TrialThe British journal of dermatology2021
Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study.
A S Van Voorhees et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.